toggle visibility Search & Display Options

Select All    Deselect All
 |   | 
Details
   print
  Record Links
Author Bisgaard, H.; Zielen, S.; Garcia-Garcia, M.L.; Johnston, S.L.; Gilles, L.; Menten, J.; Tozzi, C.A.; Polos, P. url  doi
openurl 
  Title Montelukast reduces asthma exacerbations in 2- to 5-year-old children with intermittent asthma Type Journal Article
  Year (down) 2005 Publication American Journal of Respiratory and Critical Care Medicine Abbreviated Journal Am J Respir Crit Care Med  
  Volume 171 Issue 4 Pages 315-322  
  Keywords Acetates/administration & dosage/adverse effects/*therapeutic use; Adrenal Cortex Hormones/therapeutic use; Adrenergic beta-Agonists/therapeutic use; Anti-Asthmatic Agents/administration & dosage/adverse effects/*therapeutic use; Asthma/complications/*drug therapy; Child, Preschool; Double-Blind Method; Drug Administration Schedule; Eosinophils/drug effects; Female; Humans; Male; Quinolines/administration & dosage/adverse effects/*therapeutic use; Respiratory Tract Infections/complications; Severity of Illness Index; Time Factors; Treatment Outcome  
  Abstract The PREVIA study was designed to investigate the role of montelukast, a leukotriene receptor antagonist, in the prevention of viral-induced asthma exacerbations in children aged 2 to 5 years with a history of intermittent asthma symptoms. The study was a 12-month multicenter, double-blind, parallel-group study of patients with asthma exacerbations associated with respiratory infections and minimal symptoms between episodes. Patients were randomized to receive oral montelukast 4 or 5 mg (depending on age) (n = 278) or placebo (n = 271) once per day for 12 months. Caregivers recorded children's symptoms, beta-agonist use, and health care resource use in a diary card. Over 12 months of therapy, montelukast significantly reduced the rate of asthma exacerbations by 31.9% compared with placebo. The average rate of exacerbation episodes per patient was 1.60 episodes per year on montelukast compared with 2.34 episodes on placebo. Montelukast also delayed the median time to first exacerbation by approximately 2 months (p = 0.024), and the rate of inhaled corticosteroid courses (p = 0.027) compared with placebo. Montelukast effectively reduced asthma exacerbations in 2- to 5-year-old patients with intermittent asthma over 12 months of treatment and was generally well tolerated.  
  Address Department of Pediatrics, Copenhagen University Hospital, DK-2920 Gentofte, Copenhagen, Denmark. Bisgaard@copsac.dk  
  Corporate Author Thesis  
  Impact Factor 12,996 First Author Bisgaard, H. Editor  
  Language English Summary Language Original Title  
  Series Editor Series Title Abbreviated Series Title  
  Series Volume Series Issue Senior Author Polos, P.  
  ISSN 1073-449X ISBN Medium  
  Area Expedition Conference  
  Notes PMID:15542792 Approved no  
  Call Number Serial 180  
Permanent link to this record
Select All    Deselect All
 |   | 
Details
   print

Save Citations:
Export Records: